Belzeaux Raoul, Lin Rixing, Turecki Gustavo
McGill Group for Suicide Studies, Douglas Mental Health University Institute, McGill University, 6875 boulevard LaSalle, Montreal, QC, H4H 1R3, Canada.
CNS Drugs. 2017 Apr;31(4):253-262. doi: 10.1007/s40263-017-0418-z.
Major depressive disorder (MDD) is a serious and common psychiatric disorder that affects millions of people worldwide. The most common treatment methods for MDD are antidepressant drugs, many of which act by regulating monoamines by inhibiting pre-synaptic reuptake and/or by modulating monoamine receptors. Despite advances in antidepressants and other treatment options, therapy is often based on subjective decisions made by the physician. Moreover, it requires time to determine treatment outcome and to define whether the prescribed treatment is effective. Biomarkers may help identify individuals with MDD who are more likely to respond to specific antidepressant treatment and may thus provide more objectivity in treatment decision making. MicroRNA as biomarkers of antidepressant response has engendered substantial enthusiasm. In this review, we give a detailed overview of biomarkers, particularly the major studies that have investigated microRNA in relationship to antidepressant treatment response.
重度抑郁症（MDD）是一种严重且常见的精神疾病，影响着全球数百万人。MDD最常见的治疗方法是抗抑郁药物，其中许多药物通过抑制突触前再摄取和/或调节单胺受体来调节单胺起作用。尽管抗抑郁药和其他治疗选择取得了进展，但治疗往往基于医生做出的主观决定。此外，确定治疗结果并定义所开处方的治疗是否有效需要时间。生物标志物可能有助于识别更有可能对特定抗抑郁治疗产生反应的MDD患者，从而在治疗决策中提供更多客观性。作为抗抑郁反应生物标志物的微小RNA引起了广泛关注。在本综述中，我们详细概述了生物标志物，特别是研究微小RNA与抗抑郁治疗反应关系的主要研究。
